Venn Life Sciences Holdings PLC Appointment of Non Executive Director (5034K)
September 22 2016 - 1:01AM
UK Regulatory
TIDMVENN
RNS Number : 5034K
Venn Life Sciences Holdings PLC
22 September 2016
22 September 2016
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
Appointment of Non-Executive Director
Venn Life Sciences (AIM: VENN), a growing Contract Research
Organisation (CRO) providing drug development, clinical trial
management and resourcing solutions to pharmaceutical,
biotechnology and medical device clients, announces the appointment
of Mary Sheahan as a Non-Executive Director ('NED') to the Board
with immediate effect.
Mary Blake Sheahan, aged 44, is a dedicated senior leader with
over 20 years' experience, at Executive Committee level of a
multinational publicly listed biopharmaceutical company. Mary's
most recent role was as Senior Vice President of Global Integration
and Country Manager for Ireland with Perrigo Company plc, a
NYSE-listed, $13 billion market cap leading global healthcare
supplier. In this role, she was responsible for the successful
integration of a $4.5bn acquisition of a leading European OTC
Healthcare Company with operations in 35 countries.
Prior to this, Mary was Executive Vice President and Group Head
of HR, IT, Facilities & Portfolio Assessment Management at Elan
Corporation plc prior to its merger with Perrigo in 2013. Mary is a
qualified chartered accountant having trained with KPMG.
Tony Richardson, Chief Executive Officer of Venn said: "Mary
will be a great addition to the Board in a time of great progress
and change at Venn. She has a proven track record of setting
direction, strategic decision-making and delivering results in
complex and challenging situations, across a range of disciplines
including finance, strategy and commercial functions. She will add
considerable value to our team.
Mary has confirmed that there are no other items requiring
disclosure in accordance with Schedule 2(g)(iii) to (viii) of the
AIM rules and the ESM Rules.
Current directorships Directorships or partnerships
or partnerships in the last five years
---------------------------- ---------------------------------
Madiba Consulting Limited
Elan Science Three Limited Prothena Corporation,
plc
Perrigo Holdings Limited
Perrigo Corporation Limited
Janssen Alzheimer Immunotherapy
Unlimited
Perrigo Finance plc
Mary does not hold any interests in ordinary shares of Venn.
Enquiries:
Venn Life Sciences Holdings
Plc
Allan Wood, Chairman Tel: +447185325898
Tony Richardson, Chief Executive Tel: +353 154 99
Officer 341
Davy (Nominated Adviser, ESM
Adviser and Joint Broker)
Fergal Meegan / Matthew de Vere Tel: +353 1 679
White (Corporate Finance) 6363
Orla Bolger (Corporate Broking)
Hybridan LLP (Co-Broker)
Claire Louise Noyce Tel: +44(0) 20 3764
2341
Walbrook PR Ltd Tel: +44(0)20 7933 8787
or venn@walbrookpr.com
Paul McManus Mob: +44(0) 7980
541 893
Lianne Cawthorne Mob: +44(0) 7584
391 303
About Venn Life Sciences:
Venn Life Sciences (AIM: VENN), a growing Contract Research
Organisation (CRO) providing drug development, clinical trial
management and resourcing solutions to pharmaceutical,
biotechnology and medical device clients. With dedicated operations
in France, Germany, the Netherlands, the UK, Ireland and Europe
wide representation - Venn specialises in rapid deployment and
management of multisite projects. Venn also has an innovation
division - Innovenn - focused primarily on breakthrough development
opportunities in Skin Science.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAKFLFLQKFFBBD
(END) Dow Jones Newswires
September 22, 2016 02:01 ET (06:01 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024